Condition 1: Hearing loss. Condition 2: Hearing loss. Condition 3: Hearing loss. Condition 4: Hearing loss. Other and unspecified types of non-Hodgkin lymphoma Hodgkin lymphoma Non-follicular lymphoma Malignant neoplasm of stomach
Conditions
Interventions
Intervention 1: Case groups: Sertraline, 50 mg oral tablet, starting dose with 25 mg once daily and if tolerated 50 mg per day continues for 3 months. Intervention 2: Control group: placebo, Saccharin
Prevention
Case groups: Sertraline, 50 mg oral tablet, starting dose with 25 mg once daily and if tolerated 50 mg per day continues for 3 months
Control group: placebo, Saccharin oral tablet, a daily pill for three months
Sponsors
Investigator
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with cancer who are scheduled to receive Cisplatin; aged 20 to 65 years. Exclusion criteria: previous use of Cisplatin or any ototoxic drug; patients with Head and Neck cancer; age above 65 years; patients who use hearing aids or those associated with hearing loss in the past otalgic disease; Steroid user; patients with systemic diseases such as Diabetes, Hypertension, Thyroid disease, Kidney or Liver disease; pregnant or lactating women; patients with a history of Seizure; taking Monoamine Oxidase inhibitors; concomitant use of Antidepressants drugs; history of radiotherapy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hearing frequencie. Timepoint: Before the intervention, After the intervention. Method of measurement: Distorsion product Otoacoustic Emission, High frequency tympanoaudiometery. | — |
Secondary
| Measure | Time frame |
|---|---|
| The side effects of taking Sertraline. Timepoint: Before the intervention, After the intervention. Method of measurement: Interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Karbasi
Medical System
Outcome results
None listed